Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 2
2010 1
2011 1
2012 3
2013 3
2015 6
2016 2
2017 1
2018 1
2019 4
2021 2
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Uterine primitive neuroectodermal tumor.
Aminimoghaddam S, Seifirad S, Abbasi Dezfouli G, Abbasi N, Zare Mehrjardi A, Razavi SM, Mahmoudzadeh F. Aminimoghaddam S, et al. Among authors: razavi sm. Arch Iran Med. 2015 Apr;18(4):260-2. Arch Iran Med. 2015. PMID: 25841950
Monoclonal and Polyclonal Antibodies Specific to Human Fibromodulin.
Farahi L, Ghaemimanesh F, Milani S, Razavi SM, Bayat AA, Rabbani H, Akhondi MM. Farahi L, et al. Among authors: razavi sm. Iran J Biotechnol. 2019 Jan 11;17(1):e2277. doi: 10.21859/ijb.2277. eCollection 2019 Jan. Iran J Biotechnol. 2019. PMID: 31457049 Free PMC article.
Medical oncology, history and its future in Iran.
Mirzania M, Ghavamzadeh A, Asvadi Kermani I, Ashrafi F, Allahyari A, Rostami N, Razavi SM, Ramzi M, Nemanipour G. Mirzania M, et al. Among authors: razavi sm. Arch Iran Med. 2015 Nov;18(11):799-805. Arch Iran Med. 2015. PMID: 26497380
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, Ghadiany M, Shahi F, Gharib B, Moazed V, Khosravi A, Mirpour MH, Salari S, Mortazavizadeh S, Nekoyi A, Khani M, Sadeghi A, Gharib S, Bary A, Mirzania M, Haghighat S, Razavi SM, Emami SAH, Hosseinzadeh M, Mirbolouk M, Sadighi S, Shahrasbi A, Esfahani A, Gity M, Anjidani N, Kafi H, Najafi S. Allahyari A, et al. Among authors: razavi sm. BMC Cancer. 2022 Sep 7;22(1):960. doi: 10.1186/s12885-022-09895-5. BMC Cancer. 2022. PMID: 36071409 Free PMC article. Clinical Trial.
Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.
Kazemi-Sefat GE, Keramatipour M, Vaezi M, Razavi SM, Kavousi K, Talebi A, Rostami S, Yaghmaie M, Chahardouli B, Talebi S, Mousavizadeh K. Kazemi-Sefat GE, et al. Among authors: razavi sm. Sci Rep. 2022 Jul 27;12(1):12816. doi: 10.1038/s41598-022-17232-w. Sci Rep. 2022. PMID: 35896598 Free PMC article.
A Post-Marketing Surveillance Study to Evaluate the Safety Profile of AlvotereⓇ (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy.
Shahi F, Vafaeezadeh F, Ansarinejad N, Ahmadi A, Shahriari-Ahmadi A, Ghazizadeh A, Vahedian Ardakani H, Ravanbod MR, Seifi S, Foratyazdi M, Mousavi SA, Rajabi Vahid M, Rahimi H, Seghatoleslami M, Razavi SM, Pourkhani AH, Babakhani D, Anjidani N. Shahi F, et al. Among authors: razavi sm. Curr Ther Res Clin Exp. 2021 Dec 16;96:100659. doi: 10.1016/j.curtheres.2021.100659. eCollection 2022. Curr Ther Res Clin Exp. 2021. PMID: 35035631 Free PMC article.
Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, Ghadiany M, Shahi F, Gharib B, Moazed V, Khosravi A, Mirpour MH, Salari S, Mortazavizadeh S, Nekoyi A, Khani M, Sadeghi A, Gharib S, Bary A, Mirzania M, Haghighat S, Razavi SM, Emami SAH, Hosseinzadeh M, Mirbolouk M, Sadighi S, Shahrasbi A, Esfahani A, Gity M, Anjidani N, Kaf H, Najaf S. Allahyari A, et al. Among authors: razavi sm. BMC Cancer. 2022 Dec 22;22(1):1348. doi: 10.1186/s12885-022-10455-0. BMC Cancer. 2022. PMID: 36550442 Free PMC article. No abstract available.
34 results